STOCK TITAN

Amylyx Pharmaceuticals, Inc. (AMLX) Net Income by Year

AMLX

Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7M in fiscal year 2025. This represents an increase of 52.0% from the prior fiscal year. The table below carries 5 fiscal years, from 2021 to 2025, and the quarters Amylyx Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
Net Income -$144.7M
YoY +52.0%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

AMLX Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-K
Net Income-$144.7M+52.0%-$301.7M-712.4%$49.3M+124.8%-$198.4M-125.6%-$87.9M

AMLX Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$43.4M-4.8%-$41.3M-15.0%N/A-$34.4M+52.7%-$41.4M+43.0%-$35.9M+69.8%N/A-$72.7M-448.0%-$72.7M-429.3%-$118.8M-7652.0%$4.7M$20.9M+138.9%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Amylyx Pharmaceuticals, Inc. financials

Frequently Asked Questions

What was Amylyx Pharmaceuticals, Inc.'s net income in fiscal year 2025?

Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7M in fiscal year 2025.

How fast is Amylyx Pharmaceuticals, Inc.'s net income growing?

Amylyx Pharmaceuticals, Inc. (AMLX) net income rose by 52.0% year over year, from -$301.7M to -$144.7M in fiscal year 2025.

How has Amylyx Pharmaceuticals, Inc.'s net income changed over the years?

Across the 5 fiscal years this page covers, Amylyx Pharmaceuticals, Inc. (AMLX) net income went from -$87.9M in fiscal year 2021 to -$144.7M in fiscal year 2025.

Amylyx Pharmaceuticals, Inc. (AMLX) reported -$43.4M in net income in Q2 2026. This represents a decrease of 4.8% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Amylyx Pharmaceuticals, Inc. (AMLX) reported on that line in every period on record.